biote (BTMD) Company Report

Biote reported Q3 2025 revenue of $48.0 million, a 6.7% decrease year-over-year, primarily due to a 10.4% decline in procedure revenue, while dietary supplements revenue grew 8.4% to $11.2 million.
For Q3 2025, net income was $9.2 million and diluted EPS was $0.22; adjusted EBITDA decreased 20.5% to $12.9 million, resulting in an adjusted EBITDA margin of 26.9%.
The company reiterated its fiscal 2025 guidance for revenue above $190 million and adjusted EBITDA above $50 million.
Biote repurchased approximately 1 million shares of Class A common stock at an average price of $3.28 per share and amended settlement agreements with Marcy and Dr. Gary Donovitz, achieving cash flow savings of approximately $7.5 million and $11.1 million, respectively.
The commercial team is currently at 75-80% of its planned sales rep headcount for 2025, and the attrition rate remained elevated at around 8% in Q3, similar to Q2.

Nov 5, 2025, 10:00 PM

Transcript

Biote Corp. Reports Third Quarter 2025 Financial Results and Reiterates 2025 Guidance

BTMD

Earnings

Guidance Update

Share Buyback

Biote Corp. reported Q3 2025 revenue of $48.0 million, a 6.7% decrease from the prior year, with net income of $9.2 million and diluted earnings per share of $0.22.
Adjusted EBITDA for Q3 2025 was $12.9 million, a 20.5% decrease from the prior year, resulting in an Adjusted EBITDA margin of 26.9%.
The company reiterated its 2025 financial guidance, projecting revenue above $190 million and Adjusted EBITDA above $50 million.
During the third quarter of 2025, Biote repurchased approximately one million shares of Class A common stock.

Nov 5, 2025, 9:08 PM

8-K

Biote Reports Third Quarter 2025 Financial Results

BTMD

Earnings

Guidance Update

Share Buyback

Biote reported revenue of $48.0 million, net income of $9.2 million, and diluted earnings per share of $0.22 for the third quarter ended September 30, 2025.
The company's gross profit margin improved to 71.8%, and Adjusted EBITDA was $12.9 million for the quarter.
Biote repurchased approximately one million shares of Class A common stock in the third quarter and reiterated its 2025 financial guidance, forecasting revenue above $190 million and Adjusted EBITDA above $50 million.
The company also amended settlement agreements to repurchase remaining shares from Marci Donovitz for $12.5 million (paid in October 2025) and Dr. Gary Donovitz for $18.5 million (to be paid in January 2026).

Nov 5, 2025, 9:05 PM

Press Release

Biote Corp Announces Q1 2025 Results and Strategic Restructuring

BTMD

Earnings

Revenue Acceleration/Inflection

Guidance Update

Layoffs

Q1 2025 revenue increased 4.7% to $49.0M with a gross margin of 74.3%
Net income improved to $15.8M with a diluted EPS of $0.37, reversing last year's net loss
Reaffirmed full-year guidance at $202M–$208M in revenue and $59M–$64M in adjusted EBITDA
Dietary supplements grew 25.5%, while procedure revenue declined 3.6%
Announced a strategic organizational restructuring to drive enhanced clinic growth and operational efficiency, including a 25% expansion in its field sales force
Anticipated Q2 restructuring charges of $0.6–$0.8M, with an additional minor charge expected

May 7, 2025, 9:01 PM

Transcript 8-K

biote Corp. Reports Q4 2024 Investor Presentation

BTMD

Revenue Acceleration/Inflection

Share Buyback

New Projects/Investments

Investor Presentation details Q4 2024 financial performance with $197.2M revenue, $58.2M adjusted EBITDA, and a 29.5% adjusted EBITDA margin; providing key insights into the Company’s hormone optimization business.
The presentation outlines the Q1 2025 outlook, noting expectations for moderate revenue growth and a slight decline in adjusted EBITDA compared to Q1 2024.
It also highlights strategic capital allocation initiatives, including significant share repurchase programs and investments to fortify clinical decision support and practitioner onboarding.

Mar 17, 2025, 12:00 AM

8-K

Biote Corp Announces Q4 2024 Results

BTMD

Earnings

Guidance Update

CEO Change

Fourth quarter revenue reached $49.8 million, up 9% year-over-year, with gross profit margin improving to 71.8% and net income at $3.5 million compared to the previous period; these figures reflect a strong operational performance.
The company provided 2025 guidance with revenue expectations of $202–$208 million and adjusted EBITDA in the range of $59–$64 million, noting procedure revenue growth of 2%–4% and dietary supplement revenue growth of 5%–10%.
Strategic updates included the appointment of new CEO Bret Christensen, successful integration of the Asteria Health acquisition, enhanced internal manufacturing capabilities, and the completed rollout of a new clinical decision support software platform.

Mar 12, 2025, 9:01 PM

Transcript

biote Corp. Reports Q4 2024 and Full Year 2024 Financial Results

BTMD

Earnings

Revenue Acceleration/Inflection

Guidance Update

Q4 2024 highlights included total revenue of $49.8 million and procedure revenue of $36.6 million, with a gross profit margin of 71.8% and net income of $3.5 million (EPS of $0.10), reflecting a lower net income compared to the prior quarter's $12.1 million.
Full Year 2024 results showed revenue at $197.2 million—a 6.4% increase over 2023—along with an improved net income profile, reporting a modest profit of $0.05 million (EPS of $0.09), versus a prior-year net loss of $(2.8) million.
The company also provided fiscal 2025 outlook, with revenue guidance between $202 million and $208 million and expected adjustments in EBITDA driven by ongoing operational initiatives.